Advanced in Peripheral T-Cell Lymphoma

Sherida H. Jin-Woei

Leuven, VLG, BE 
Advanced in Peripheral T-Cell Lymphoma
Leuven, VLG, BE 
OverviewLocationsClinical Research

Overview

Sherida Jin-Woei practices in Leuven, Belgium. Ms. Jin-Woei is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are T-Cell Lymphoma, Non-Hodgkin Lymphoma, Histiocytosis, and Peripheral T-Cell Lymphoma.

Her clinical research consists of co-authoring 41 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Peripheral T-Cell Lymphoma.

Gender
Female

Locations

Leuven, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Enrollment Status: Approved_for_marketing
Publish Date: December 18, 2024
Intervention Type: Drug
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Enrollment Status: Terminated
Publish Date: October 24, 2024
Intervention Type: Biological
Study Drug: GEN3009
Study Phase: Phase 1/Phase 2
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

41 Total Publications

Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment.
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment.
Journal: Blood cancer journal
Published: November 01, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Jin-Woei's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile